Scilex Holding Company’s Commitment to Stockholder Value
Scilex Holding Company, a pivotal player in the non-opioid pain management domain, has been actively focused on protecting its stockholder rights. The management team is fully committed to enhancing stockholder value and addressing the issues concerning manipulative practices, including naked short selling of Scilex common stock. This effort is vital not only for the company's reputation but also for the interests of each individual stockholder.
Announcement of Record Date for Dividend
The company recently announced a record date specifically for the dividend of preferred stock to eligible stockholders. This step underscores Scilex's ongoing efforts to reward its investors while navigating the complexities of stock trading. Although the record date has been set, adjustments may still be required at the discretion of the board of directors until the actual payment is confirmed.
Understanding the Current Stock Situation
As of now, approximately 197 million shares of Scilex common stock are outstanding. Notably, about 76 million shares were distributed as dividend shares from Sorrento Therapeutics, Inc., with trading restrictions in place until January 2025. Additionally, Scilex has repurchased around 60 million shares since last September, thereby removing them from public trading, which is aimed at stabilizing share prices and enhancing overall value for stockholders.
Addressing Short Selling Concerns
Recent reports suggest that over 12 million shares of Scilex common stock are currently being sold short, which raises significant concerns regarding market manipulation. Moreover, over 10 million dividend shares have been identified as being involved in naked short selling activities. The management believes that beyond just numbers, these manipulative practices undermine stockholder confidence and the integrity of market operations.
The Role of Regulatory Compliance
To combat these issues, Scilex is taking several strategic measures. The company's approach includes working closely with regulatory bodies to ensure compliance and transparency. They aim to gather accurate information on stock trades and highlight instances of illegal practices such as naked short selling. All Scilex shares should be strictly regulated against practices that involve lending or hypothecation without proper authorization.
Empowering Stockholders
To further empower stockholders, Scilex is providing actionable information that can be used to address these challenges effectively. Stockholders are encouraged to consider options like recalling shares from brokerage lending programs, opting for cash accounts, or transferring shares to a Direct Registration System (DRS) account. These steps not only help in asserting their rights but also play a vital role in enhancing the stability of their investments.
Steps to Recall Shares
Scilex is guiding its stockholders on how to draft effective communication with their brokerage firms to initiate the recall of loaned shares. Stockholders can utilize sample letters provided by Scilex, which outline the necessary details to ensure their requests are fulfilled. By taking these steps, investors can better protect their investments against manipulative market practices.
Scilex's Innovative Approach to Pain Management
As a company dedicated to non-opioid pain therapy, Scilex is continually advancing its product offerings. Their flagship products include ZTlido®, ELYXYB®, and Gloperba®—all designed to provide effective pain management solutions to patients. Furthermore, Scilex is in the process of developing several promising candidates aimed at addressing chronic pain conditions, which are often unmanageable through traditional opioid therapies.
Contact Information
For more information about Scilex Holding Company, stockholders and potential investors can reach out to the company directly through their established communication channels. With headquarters located in Palo Alto, California, the management team remains accessible to address any inquiries and facilitate transparency regarding operations and market conditions.
Frequently Asked Questions
What measures is Scilex taking against short selling?
Scilex is actively engaging with regulatory authorities to tackle misleading practices and foster transparency in trading activities.
How can stockholders protect their interests?
Stockholders can reclaim their shares from lending programs and direct them to cash accounts or DRS accounts for added security.
What are the numbers indicating about Scilex's shares?
There are approximately 12 million shares sold short and over 10 million dividend shares sold in naked short scenarios, compromising shareholder value.
What products does Scilex offer?
Scilex markets ZTlido®, ELYXYB®, and Gloperba®, which cater to pain management without relying on opioids.
Where can I find more information about Scilex?
Visit Scilex’s official website or contact their investor relations for additional insights and updates on their operations and stockholder rights.
